Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests

Introduction: Imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (CML), may adversely affect thyroid gland function. To date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. The aim of...

Full description

Bibliographic Details
Main Authors:	Mohammad Ali Mashhadi, Mahmoud Ali Kaykhaei, Mahdi Mohammadi, Mahdi Hashemi, Tahere Mohamadi Fatide
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2014-09-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	Chronic myelogenous leukemia Imatinib mesylate Thyroid function tests
Online Access:	https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/417

Similar Items

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
by: Abhilash Chandra, et al.
Published: (2020-04-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-04-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-01-01)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib
by: Phatchanat Klaihmon, et al.
Published: (2024-02-01)

Imatinib-Induced Psoriasis
by: Figen Atalay, et al.
Published: (2013-06-01)

Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib
by: Naveed Ali, et al.
Published: (2016-03-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
by: Alexis Tracy, MD, et al.
Published: (2022-12-01)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Kota Yoshifuji, et al.
Published: (2022-10-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Outcome of imatinib mesylate in women with child-bearing age diagnosed with chronic myeloid leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2021-01-01)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
by: Hyacinthe Johnson-Ansah, et al.
Published: (2022-08-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature
by: Narender Kumar, et al.
Published: (2013-01-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
by: Rita Ahmad, et al.
Published: (2021-04-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

Frequency of the BCR/ABL rearrangements and associated alterations detected by FISH during monitoring of patients taking imatinib mesylate in isolation Freqüência do rearranjo BCR/ABL e alterações associadas detectadas por FISH no monitoramento de pacientes em uso exclusivo do mesilato de imatinibe
by: Cristina B. Vendrame-Goloni, et al.
Published: (2006-06-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
by: Abolghasem Allahyari, et al.
Published: (2016-03-01)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017-06-01)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
by: Takaaki Ono
Published: (2021-10-01)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Chronic myelogenous leukemia in a child following treatment for bilateral retinoblastoma
by: Haitham Hilal Al-Mahrouqi, et al.
Published: (2021-01-01)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
by: Xin P, et al.
Published: (2017-04-01)

Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection
by: Zhuan - Bo Luo, et al.
Published: (2017-11-01)

Wnt Signaling Pathway and Chronic Myelogenous Leukemia
by: HOU Yan, et al.
Published: (2019-02-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)